Previous 10 | Next 10 |
Acer Therapeutics ( NASDAQ: ACER ) is trading ~5% higher after the company began two Phase 2 investigator-sponsored trials evaluating ACER-801 (osanetant) in men with adenocarcinoma of the prostate. The two-trials are - The POSH-MAP, which is Pilot of Osanetant for Severi...
NEWTON, Mass., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced the init...
Acer Therapeutics ( NASDAQ: ACER ) said it regained compliance with Nasdaq's rule of $35M market value of listed securities requirement for continued listing on the exchange. The company added that the listing matter is now closed and the previously-scheduled hearing before the Na...
NEWTON, Mass., Dec. 29, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced that The...
Despite US FDA approval of Acer Therapeutics' ( NASDAQ: ACER ) Olpruva (sodium phenylbutyrate) for urea cycle disorders, the company's stock is down 33% in Tuesday afternoon trading. The approval triggers the availability of a $42.5M loan term agreement with affiliate...
New FDA-approved formulation for patients living with urea cycle disorders $42.5 million of non-dilutive debt funding available to Acer that, if drawn, would extend cash runway into H2 2023 NEWTON, Mass. and GENEVA, Dec. 27, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasda...
The U.S. Food and Drug Administration (FDA) has greenlighted Olpruva, being developed by Acer Therapeutics ( NASDAQ: ACER ) and Swiss biotech Relief Therapeutics ( OTCQB:RLFTF ) ( OTCQB:RLFTY ) as a treatment for patients with urea cycle disorders (UCD). The oral treatment, al...
NEWTON, Mass., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases with significant unmet medical needs, today announced that it...
Acer Therapeutics press release ( NASDAQ: ACER ): Q3 GAAP EPS of -$0.31 beats by $0.37 . Cash and cash equivalents were $6.4M as of September 30, 2022, compared to $12.7M as of December 31, 2021. Acer believes its cash and cash equivalents available as of September...
NEWTON, Mass., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases with significant unmet medical needs, today reported fi...
News, Short Squeeze, Breakout and More Instantly...
Acer Therapeutics Inc. Company Name:
ACER Stock Symbol:
NASDAQ Market:
Acer Therapeutics Inc. Website:
AERWINS Technologies Inc. (AWIN) is expected to report for Q1 2024 Minera IRL Ltd ADR (MRLLY) is expected to report for quarter end 2023-09-30 SmileDirectClub, Inc. - Ordinary Shares - Class A (SDCCQ) is expected to report $-0.1 for Q3 2023 NextPlay Technologies Inc. (NXTP) is expecte...
INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...
Acer Therapeutics Inc. (ACER) is expected to report $-0.13 for Q3 2023